Nuvectis secures drug rights worth $1.461 billion
- Nuvectis executed an exclusive licensing agreement with Haisco Pharmaceutical Group for ex-China rights to two clinical-stage drug candidates.
- Following the deal announcement, market investors drove the company's share price up to $13.82 near its yearly high.
- The transaction expands the clinical pipeline into oncology and complement-mediated diseases to accelerate late-stage medical asset development.
Biopharmaceutical firm Nuvectis (NASDAQ:NVCT) licensed exclusive ex-China rights for two clinical drug assets in a deal valued up to $1.461 billion.
The agreement expands the corporate drug pipeline beyond its previous early-stage focus into late-stage oncology and complement-mediated disease therapies.
"Our in-licensing represents an expansion of Nuvectis' pipeline and strategy," said Nuvectis Chairman and CEO Ron Bentsur.
Under the agreement terms, the deal includes upfront payments of up to $40 million and extends key composition patents out to 2043.
The company noted that the transaction remains subject to specific financing conditions, but following the announcement Nuvectis share price was up at $13.82.
The newly acquired assets include a once-daily oral inhibitor called NXP100 and a brain-penetrant tumor treatment designated as NXP200.
Both medical compounds are currently undergoing separate active clinical evaluations within China under the management of Haisco Pharmaceutical Group.
